

01-22-04

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.  
RLL-297US

In Re Application Of:

KHANNA et al.

Serial No.  
10/690,897

Filing Date  
10/22/2003

Examiner  
TBA

Group Art Unit  
TBA

Title: AMORPHOUS FORM OF ESOMEPRAZOLE MAGNESIUM



Address to:

Assistant Commissioner for Patents  
Washington, D.C. 20231

**37 CFR 1.97(b)**

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

**37 CFR 1.97(c)**

2. ☐ The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:
- ☐ the statement specified in 37 CFR 1.97(e);
- OR**
- ☐ the fee set forth in 37 CFR 1.17(p).

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.  
RLL-297US

In Re Application:

KHANNA et al.

Serial No.

10/690,897

Filing Date

10/22/2003

Examiner

TBA

Group Art Unit

TBA

**AMORPHOUS FORM OF ESOMEPRAZOLE MAGNESIUM**

**Payment of Fee**

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of \_\_\_\_\_ is attached.
- ☐ The Assistant Commissioner is hereby authorized to charge and credit Deposit Account No. \_\_\_\_\_ as described below. A duplicate copy of this sheet is enclosed.
- ☐ Charge the amount of \_\_\_\_\_
- ☐ Credit any overpayment.
- ☐ Charge any additional fee required.

**Certificate of Transmission by Facsimile\***

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (F


\_\_\_\_\_  
(Date)

\_\_\_\_\_  
Signature

\_\_\_\_\_  
Typed or Printed Name of Person Signing Certificate

**Certificate of Mailing by First Class Mail**

I certify that this document and fee is being deposited with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

  
Signature of Person Mailing Correspondence

Kim Campbell

\_\_\_\_\_  
Typed or Printed Name of Person Mailing Certificate

\*This certificate may only be used if paying by deposit account.

  
Signature

Dated: January 20 2004

Jayadeep R. Deshmukh, Esq.  
Reg. No. 34,507  
Ranbaxy Pharmaceuticals Inc.  
600 College Road East, Suite 2100  
Princeton, New Jersey 08540  
Telephone: 609-720-5608  
Facsimile: 609-514-9779

CC:

# INFORMATION DISCLOSURE CITATION

Docket No.: RLL-297US

Serial No.: 10/690,897

Applicants: Khanna *et al.*

Filed: 10/22/2003

Group:

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A1	US 4,255,431 ✓	3/10/1981	Junggren <i>et al.</i>	424	263	
	A2	US 4,738,974 ✓	4/19/1988	Brändström	514	338	
	A3	US 5,714,504	2/3/1998	Lindberg <i>et al.</i>	514	338	
	A4	US 5,714,505 ✓	2/3/1998	Hasselkus	514	338	
	A5	US 6,124,464 ✓	9/26/2000	Högberg <i>et al.</i>	546	273.7	
	A6	US 6,369,085 ✓	4/9/2002	Cotton <i>et al.</i>	514	338	

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES   NO	
	B1	WO 94/27988 ✓	12/8/1994	PCT	C07D	401/12		
	B2	WO 96/02535 ✓	2/1/1996	PCT	C07D	401/12		
	B3	WO 98/54171	12/3/1998	PCT	C07D	401/12		

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)


EXAMINER	DATE CONSIDERED
----------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.